+65 3158 9940
1300 798 820
+64 9801 0299
Los Angeles, Calif. and Melbourne Australia – July, 2010 – Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline
Melbourne, 7 June 2010: Melbourne pharmaceutical company Specialised Therapeutics Australia (STA) wishes to announce a change in the Pharmaceutical Benefits Scheme (PBS) listing for its lead product ABRAXANE® (nanoparticle albumin-bound paclitaxel).
MELBOURNE, May, 2010: An international study of world-leading breast cancer drug ABRAXANE ® (nanoparticle albumin-bound paclitaxel) has shown promising results for patients with advanced pancreatic cancer when used in combination with Gemcitabine.
CANCER DRUG ABRAXANE® IN FOCUS AT INTERNATIONAL CONFERENCE Delegates to hear trial results for future possible ABRAXANE indications including lung cancer and melanoma Melbourne: 27 May 2010: World leading advanced breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) will be in focus at a leading international medical conference in Chicago next week. Specialised Therapeutics Australia Pty Ltd (STA), which
LOS ANGELES and MELBOURNE – March 18, 2010: An international lung cancer trial has shown positive results in those patients treated with the leading breast cancer drug ABRAXANE in combination with carboplatin.
The following story appeared on Channel 7’s current affairs program Today Tonight in March 2010. Click here to view.
Melbourne, February 2010: A leading Australian breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been granted orphan drug status by the Therapeutic Goods Administration (TGA) for pancreatic cancer.